Angiotensin Peptides Potentiate SARS-CoV-2 Spike–AXL Receptor Interaction: Technical Insights and Implications

Study Background and Research Question

The renin-angiotensin system (RAS) regulates blood pressure and fluid homeostasis through a cascade of peptide hormones, including angiotensin II and its derivatives. The COVID-19 pandemic has brought renewed attention to the RAS because SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) as a primary receptor for cell entry. However, recent research has identified alternative spike protein receptors, such as neuropilin-1 (NRP1) and AXL, that may also facilitate viral infection—especially in tissues with low ACE2 expression. The reference study (Oliveira et al., 2025) investigates how different angiotensin peptides influence the interaction between the SARS-CoV-2 spike protein and these host receptors, with a specific focus on the effect of truncated RAS peptide fragments.

Key Innovation from the Reference Study

This work provides the first systematic evidence that naturally occurring angiotensin peptides, including short C- and N-terminal fragments, can markedly enhance the binding of the SARS-CoV-2 spike protein to the AXL receptor. Unlike prior studies that emphasized the ACE2 axis, this research demonstrates that certain angiotensin fragments—generated by physiological cleavage—are more potent than full-length peptides in facilitating spike–AXL interactions (Oliveira et al., 2025). These findings expand understanding of both RAS biology and the molecular determinants of viral tropism.

Methods and Experimental Design Insights

The authors employed antibody-based binding assays to systematically compare the effects of angiotensin peptides of varying lengths and modifications on spike protein binding to three host receptors: ACE2, NRP1, and AXL. Key experimental features included:

• Use of recombinant SARS-CoV-2 spike protein and immobilized host receptors for quantifying binding events.
• Assessment of full-length angiotensin I (1–10), angiotensin II (1–8), and truncated peptides such as angiotensin (1–7), (1–6), angiotensin III (2–8), IV (3–8), (2–7), and (5–7)—the latter corresponding to the H2N-Ile-His-Pro-OH sequence.
• Testing peptide variants with substitutions or phosphorylation at tyrosine position 4 to probe structure–function relationships.

This systematic peptide panel enabled the identification of specific fragments and modifications that maximize spike–AXL binding enhancement.

Core Findings and Why They Matter

The principal findings are as follows:

• Angiotensin II (1–8) increased spike–AXL binding two-fold, but not spike–ACE2 or spike–NRP1 binding (paper).
• C-terminal truncated peptides angiotensin (1–7) and (1–6) retained similar enhancement of spike–AXL binding, suggesting the C-terminal phenylalanine is not essential for this activity.
• N-terminal truncated peptides—angiotensin III (2–8), IV (3–8), (2–7), and (5–7)—produced even greater enhancement, with angiotensin IV (3–8) achieving a 2.7-fold increase in spike–AXL binding (paper).
• Tyrosine-4 modifications (phosphorylation or substitution with valine) further amplified spike–AXL binding, implicating the role of this residue in modulating peptide–receptor interaction.
• Angiotensin IV also enhanced spike binding to ACE2 and NRP1, but the effect was most pronounced for AXL.

These results suggest that endogenous RAS peptides, especially truncated forms like Angiotensin 1/2 (5-7) (H2N-Ile-His-Pro-OH), could influence SARS-CoV-2 infectivity in tissues expressing AXL. This reveals a mechanistic bridge between cardiovascular peptide signaling and viral pathogenesis, potentially explaining observed associations between RAS imbalance and COVID-19 severity (paper).

Comparison with Existing Internal Articles

Recent internal resources have addressed the role of Angiotensin 1/2 (5-7) as a model peptide for RAS and hypertension research. For example, "Angiotensin 1/2 (5-7): Precision Tools and Novel Mechanisms" contextualizes the H2N-Ile-His-Pro-OH peptide as a research tool for dissecting molecular mechanisms in cardiovascular and viral pathogenesis models. The current reference study directly supports and extends these applications by providing quantitative evidence of this peptide's involvement in spike–AXL binding enhancement. Similarly, "Angiotensin 1/2 (5-7): Validated Vasoconstrictor Peptide" highlights its high purity and utility in RAS signaling pathway studies, aligning with the mechanistic focus of the reference paper.

Protocol Parameters

• binding assay | 1–100 μM peptide concentration | RAS–viral entry models | Reflects dose ranges used to observe spike–AXL binding enhancement | paper
• binding assay | 2-fold increase in spike–AXL binding with angiotensin II | AXL-expressing cell models | Documents the magnitude of enhancement for experimental design | paper
• peptide storage | −20°C solid; short-term solutions | All biochemical assays | Ensures peptide stability and reproducibility | product_spec
• peptide solubility | ≥50 mg/mL in water or ethanol, ≥36.5 mg/mL in DMSO | In vitro and cell-based assays | Supports preparation at experimental concentrations without precipitation | product_spec
• binding assay | Start at 1–10 μM for N-terminal truncated peptides | Viral pathogenesis and cardiovascular signaling cross-assays | Recommended screening range for sensitivity and specificity | workflow_recommendation

Why this cross-domain matters, maturity, and limitations

The demonstration that angiotensin peptides, classically studied in the context of blood pressure regulation, can enhance SARS-CoV-2 spike binding to AXL highlights a key bridge between cardiovascular and infectious disease research domains. The maturity of this evidence is supported by systematic binding assays and quantitative comparisons of peptide variants (paper). However, the study is limited to in vitro biochemical models. Translational relevance to in vivo infection dynamics, patient heterogeneity, or therapeutic modulation of RAS peptides remains to be established. Additionally, while the enhancement effect is robust in binding assays, the downstream consequences for viral entry efficiency and pathogenesis require further investigation in cellular and animal models.

Limitations and Transferability

Key limitations of the reference study include:

• Use of recombinant proteins and immobilized receptors, which may not fully recapitulate the complexity of membrane-bound receptor dynamics in living cells.
• Lack of direct measurement of infection rates or viral replication following peptide treatment.
• Peptide concentrations applied are higher than typical physiological plasma levels, though local concentrations at tissue interfaces are unknown.

Researchers should interpret the enhancement of spike–AXL binding as a mechanistic insight rather than direct evidence of altered viral infectivity in vivo. For transferability, the findings are most relevant as a basis for further studies using cell-based infection models or animal systems.

Research Support Resources

To model the effects of angiotensin peptides on spike–receptor interactions, researchers can utilize Angiotensin 1/2 (5-7) (SKU A1049), a high-purity H2N-Ile-His-Pro-OH peptide suitable for RAS signaling and viral entry assays (product_spec). This peptide is also cited in internal resources for its robust solubility and reproducibility in cardiovascular and viral pathogenesis models. For detailed assay guidance and workflow recommendations, see "Practical Solutions for Reliable Cell Assays". Always refer to the latest literature for protocol optimization based on emerging mechanistic evidence.